GrabAGun To Report Second Quarter 2025 Financial Results
Management will host a conference call at 4:30 PM ET the same day to discuss the results. The live webcast and replay will be accessible on the Company's Investor Relations website at investors.grabagun.com.
Marc Nemati, CEO of GrabAGun, commented, 'We are excited to share our financial results and host our first earnings call as a newly public company. This milestone provides us with enhanced access to capital markets and strategic resources to accelerate our growth and deliver value to shareholders. Our strategy remains focused on strategic acquisitions that complement our platform, continued investment in our technology infrastructure, and capturing a larger share of the F&A market by serving mobile-first enthusiasts, sportsmen, and defenders nationwide."
About GrabAGun
We are defenders. We are sportsmen. We are outdoorsmen. We believe that it is our American duty to help everyone, from first-time buyers to long-time enthusiasts, understand and legally secure their firearms and accessories. That's why our arsenal is fully packed, consistently refreshed, and always loaded with high-quality, affordable firearms and accessories. Industry-leading brands that GrabAGun works with include Smith & Wesson Brands, Sturm, Ruger & Co., SIG Sauer, Glock, Springfield Armory and Hornady Manufacturing, among others.
GrabAGun is a fast growing, digitally native eCommerce retailer of firearms and ammunition, related accessories and other outdoor enthusiast products. Building on its proprietary software expertise, GrabAGun's eCommerce site has become one of the leading firearm retail websites. In addition to its eCommerce excellence, GrabAGun has developed industry-leading solutions that revolutionize supply chain management, combining dynamic inventory and order management with AI-powered pricing and demand forecasting. These advancements enable seamless logistics, efficient regulatory compliance and a streamlined experience for customers.
Forward-Looking Statements
Any statements other than statements of historical fact contained herein are forward-looking statements. Such forward-looking statements include, but are not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding GrabAGun held by GrabAGun's management team and the products and markets, future financial condition, expected future performance and market opportunities of GrabAGun. These forward-looking statements generally are identified by the words 'anticipate,' 'believe,' 'could,' 'expect,' 'estimate,' 'future,' 'intend,' 'may,' 'might,' 'plan,' 'predict,' 'project,' 'should,' 'will,' 'would,' 'will likely result,' and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation: (i) changes in business, market, financial, political and legal conditions, (ii) changes in GrabAGun's relationships with its vendor partners, the availability of their products and the terms of any agreements governing those relationships, (iii) negative publicity or broader changes in public perceptions about GrabAGun or the firearms industry as a whole, (iv) changes in laws and regulations affecting GrabAGun's business, (v) risk of loss of key influencers, media outlets and promoters of GrabAGun's business or a loss of reputation of GrabAGun or reduced interest in the mission and values of GrabAGun and the segment of the consumer marketplace it intends to serve, (vi) risks of product liability or regulatory lawsuits relating to GrabAGun's products, (vii) demand for GrabAGun's current and future product offerings, (viii) the ability to implement business plans, growth, marketplace and other expectations, and identify and realize additional opportunities, (ix) risks related to GrabAGun's potential inability to achieve or maintain profitability and generate significant revenue, (x) expectations with respect to future operating and financial performance and growth, (xi) the ability of GrabAGun to maintain and obtain, as necessary, any permits necessary for the conduct of GrabAGun's business, including federal firearm licenses issued pursuant to the Gun Control Act, 18 USC 921 et seq. and special occupational taxpayer stamps issued pursuant to the National Firearms Act, 26 USC 5849 et seq., and (xii) the risk of economic downturn, increased competition, a changing regulatory landscape and related impacts that could occur in the highly competitive consumer marketplace, both online and through 'brick and mortar' operations. The foregoing list of factors is not exhaustive. Recipients should carefully consider such factors and the other risks and uncertainties described in the 'Risk Factors' section of the Registration Statement on Form S-4, as amended, filed by GrabAGun, including the definitive proxy/prospectus declared effective by the United States Securities and Exchange Commission ('SEC') on June 20, 2025 and other documents filed or to be filed by GrabAGun from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Recipients are cautioned not to put undue reliance on forward-looking statements, and GrabAGun does not assume any obligation to, nor intends to, update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by U.S. federal securities law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Why Anheuser-Busch InBev Stock Crashed Today
Key Points Anheuser-Busch InBev reported declining volumes of beer shipped in Q2. Revenue still increased, and at least one version of earnings was up. GAAP profits fell far short of what the company calls its "underlying profit." 10 stocks we like better than Anheuser-Busch InBev/NV › Shares of Anheuser-Busch InBev (NYSE: BUD), the multinational beverages (specifically, beer) stock, tumbled 11.8% through 10:05 a.m. ET Thursday after the company reported declining volumes of beer shipped in the second quarter and weaker-than-expected revenue. Analysts had forecast Anheuser-Busch would earn $0.95 per share on $15.3 billion in sales. Earnings edged out expectations at $0.98, but revenue was only $15 billion. Anheuser-Busch InBev Q2 earnings Not all the news was bad. Anheuser-Busch InBev noted that actual revenue increased 3% year over year in Q2, and "normalized EBITDA" was up 6.5%, with EBITDA margins expanding to 35.3%. Reported revenue, however, was hurt by unfavorable currency exchange rates, meaning a weak U.S. dollar. That depressed real revenue growth to just 2.1%. The company said its "underlying profit" grew 7.7% to $1.95 billion, and underlying earnings per share grew 8.7% as the company bought back stock in the quarter. At Anheuser-Busch InBev, "underlying profit" basically translates as non-GAAP (adjusted) earnings, however -- and investors are treating the numbers as such. Anheuser-Busch doesn't make it easy to figure out what its actual earnings as calculated according to generally accepted accounting principles (GAAP) were, but according to data from S&P Global Market Intelligence, they were only $0.82 per share. Is Anheuser-Busch InBev stock a buy? And now you see why investors are upset. Whatever the "underlying" or "normalized EBITDA" numbers say, Anheuser-Busch InBev's actual profit for Q2 was 16% lower than the headline number. Granted, the stock doesn't look too expensive at just over 18 times earnings. But analysts only see the stock growing earnings at 12.5% over the next five years -- and right now, earnings are heading in the opposite direction, not growing, but shrinking. And with a trend like that, it's hard to call the stock a buy. Should you invest $1,000 in Anheuser-Busch InBev/NV right now? Before you buy stock in Anheuser-Busch InBev/NV, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Anheuser-Busch InBev/NV wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Anheuser-Busch InBev Stock Crashed Today was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q2 CY2025, but sales were flat year on year at $12.27 billion. The company's full-year revenue guidance of $47 billion at the midpoint came in 1.6% above analysts' estimates. Its non-GAAP profit of $1.46 per share was 32.6% above analysts' consensus estimates. Is now the time to buy Bristol-Myers Squibb? Find out in our full research report. Bristol-Myers Squibb (BMY) Q2 CY2025 Highlights: Revenue: $12.27 billion vs analyst estimates of $11.38 billion (flat year on year, 7.8% beat) Adjusted EPS: $1.46 vs analyst estimates of $1.10 (32.6% beat) The company lifted its revenue guidance for the full year to $47 billion at the midpoint from $46.3 billion, a 1.5% increase Management lowered its full-year Adjusted EPS guidance to $6.50 at the midpoint, a 5.1% decrease Operating Margin: 14.5%, up from 12.8% in the same quarter last year Market Capitalization: $93.57 billion Company Overview With roots dating back to 1887 and a transformative merger in 1989 that gave the company its current name, Bristol-Myers Squibb (NYSE:BMY) discovers, develops, and markets prescription medications for serious diseases including cancer, blood disorders, immunological conditions, and cardiovascular diseases. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Regrettably, Bristol-Myers Squibb's sales grew at a mediocre 6.5% compounded annual growth rate over the last five years. This was below our standard for the healthcare sector and is a tough starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Bristol-Myers Squibb's recent performance shows its demand has slowed as its annualized revenue growth of 2.7% over the last two years was below its five-year trend. We can better understand the company's revenue dynamics by analyzing its most important segment, Growth Portfolio. Over the last two years, Bristol-Myers Squibb's Growth Portfolio revenue averaged 17.4% year-on-year growth. This segment has outperformed its total sales during the same period, lifting the company's performance. This quarter, Bristol-Myers Squibb's $12.27 billion of revenue was flat year on year but beat Wall Street's estimates by 7.8%. Looking ahead, sell-side analysts expect revenue to decline by 5.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will face some demand challenges. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Operating Margin Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. Bristol-Myers Squibb was profitable over the last five years but held back by its large cost base. Its average operating margin of 9.1% was weak for a healthcare business. On the plus side, Bristol-Myers Squibb's operating margin rose by 6.9 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming into its more recent performance, however, we can see the company's margin has decreased by 1.6 percentage points on a two-year basis. If Bristol-Myers Squibb wants to pass our bar, it must prove it can expand its profitability consistently. In Q2, Bristol-Myers Squibb generated an operating margin profit margin of 14.5%, up 1.7 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Bristol-Myers Squibb's EPS grew at an unimpressive 3.2% compounded annual growth rate over the last five years, lower than its 6.5% annualized revenue growth. We can see the difference stemmed from higher interest expenses or taxes as the company actually improved its operating margin and repurchased its shares during this time. In Q2, Bristol-Myers Squibb reported adjusted EPS at $1.46, down from $2.07 in the same quarter last year. Despite falling year on year, this print easily cleared analysts' estimates. Over the next 12 months, Wall Street expects Bristol-Myers Squibb's full-year EPS of $6.73 to shrink by 5%. Key Takeaways from Bristol-Myers Squibb's Q2 Results We were impressed by how significantly Bristol-Myers Squibb blew past analysts' EPS expectations this quarter. We were also excited its revenue outperformed Wall Street's estimates by a wide margin. On the other hand, full-year EPS guidance was lowered. Zooming out, we think this was a mixed print. The market seemed to be hoping for more, and the stock traded down 3.9% to $44.21 immediately following the results. Should you buy the stock or not? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Dream Finders Homes: Riding Out the Storm
Key Points Dream Finders reported solid growth in revenue and home closings, but higher expenses weighed on earnings. The company is following its playbook through the downturn, completing two acquisitions in the quarter. Dream Finders has ample resources to be opportunistic while housing is slow, but investors shouldn't expect a turnaround until macro forces realign and home buyers return to the market. 10 stocks we like better than Dream Finders Homes › Here's our initial take on Dream Finders Homes (NYSE: DFH) financial report. Key Metrics Metric Q2 2024 Q2 2025 Change vs. Expectations Revenue $1.06 billion $1.15 billion 9% Beat Earnings per share $0.81 $0.56 (31%) Missed Home closings 2,031 2,232 10% n/a Net new orders 1,712 1,938 13% n/a Dream Finders Remains On Course Despite Difficult Market Dream Finders grew revenue by 9% and home closings by 10% in what is a difficult housing environment, but higher homebuilding cost of sales and financial services expense ate into profitability. Homebuilding gross margin fell 250 basis points to 16.5%. Elevated interest rates, an uncertain economy, and pressures from soaring costs on home building supplies and labor have created what CEO Patrick Zalupski called "perhaps the most challenging environment in the past three years." Dream Finders continues to execute on its plan despite the downturn. In the quarter, the company closed deals for Alliant National Title Insurance Co. and Green River Builders, bringing its total to 10 acquisitions in the past six years. Alliant opens up new revenue sources, while Green River expands Dream Finders' presence in the fast-growing Atlanta area. The company also repurchased more than 700,000 shares for $16 million during the period. Immediate Market Reaction Investors knew going in that this was a tough housing market, and the results had little impact on sentiment. Dream Finders stock is down about 1% in early Thursday trading. What to Watch The big question facing homebuilders is when the housing market will turn. On Wednesday, the Federal Reserve held rates steady, and the odds of a September rate cut fell slightly, opening up the possibility of higher for longer on interest rates. Dream Finders ended the quarter with a backlog of 2,513 homes valued at $1.2 billion and reiterated its guidance for about 9,250 home closings in 2025. If the market remains weak, expect the company to continue to hunt for acquisition candidates in its core Sun Belt markets in anticipation of an eventual turnaround. The company cannot control the macro environment, and it is unlikely to see oversized growth until buyers return. But Dream Finders appears to be holding serve in a difficult climate, which is about the best investors can hope for for now. Helpful Resources Full earnings report Investor relations page Additional coverage Should you invest $1,000 in Dream Finders Homes right now? Before you buy stock in Dream Finders Homes, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Dream Finders Homes wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Lou Whiteman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Dream Finders Homes. The Motley Fool has a disclosure policy. Dream Finders Homes: Riding Out the Storm was originally published by The Motley Fool Sign in to access your portfolio
